TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22974389

Group type: EXPERIMENTAL
Intervention: Contact lens‐based sensor (CLS) for monitoring of 24‐hr intraocular pressure (IOP) fluctuations
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fellow eye (control)
Number of subjects: 20
Study: 19144727

Group type: EXPERIMENTAL
Intervention: 40 chews
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 25 chews
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 10 chews
Number of subjects: 13
Study: 17694802

Group type: EXPERIMENTAL
Intervention: Low dose ketamine 0.3 mg/kg intravenously before the start of operation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low dose ketamine 0.3 mg/kg intravenously at the end of operation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo saline i.v. before the incision
Number of subjects: 90
Study: 15082128

Group type: EXPERIMENTAL
Intervention: Standard care + pain booklet
Number of subjects: 406

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 406
Study: 11549529

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate-salmeterol combination therapy (FSC) administered twice daily (100 microg of fluticasone propionate and 50 microg of salmeterol)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate-salmeterol combination therapy (FSC) administered twice daily
Number of subjects: 423

Group type: COMPARATOR
Intervention: Montelukast (10 mg once daily)
Number of subjects: 423
Study: 9668941

Group type: EXPERIMENTAL
Intervention: Behavioral marital therapy (BMT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Interactional couples therapy group
Number of subjects: 36

Group type: COMPARATOR
Intervention: No-marital-treatment control group
Number of subjects: 36
Study: 8062318

Group type: EXPERIMENTAL
Intervention: Extended-release ketoprofen 200 mg once daily for 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Piroxicam 20 mg once daily for 3 weeks
Number of subjects: 60
Study: 31174236

Group type: EXPERIMENTAL
Intervention: Ofatumumab and bendamustine (arm A)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Ofatumumab, bendamustine, and bortezomib (arm B)
Number of subjects: 128
Study: 27918931

Group type: EXPERIMENTAL
Intervention: Encourage Autonomous Self‐Enrichment program for 12 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard education provided by nurses
Number of subjects: 65
Study: 25447626

Group type: EXPERIMENTAL
Intervention: Valsartan and nateglinide
Number of subjects: 9306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9306
Study: 23132842

Group type: EXPERIMENTAL
Intervention: Boys (n=54)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Girls (n=62)
Number of subjects: 116
Study: 22018765

Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 39
Study: 18485819

Group type: EXPERIMENTAL
Intervention: Stellate-ganglion block
Number of subjects: 13
Study: 16936546

Group type: EXPERIMENTAL
Intervention: ArteFill
Number of subjects: 251

Group type: COMPARATOR
Intervention: Bovine collagen dermal filler
Number of subjects: 251
Study: 14513451

Group type: EXPERIMENTAL
Intervention: 90/90 pillow
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 40
Study: 11213545

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.2 microgram/kg i.v. as premedication and 0.15 microgram/kg during maintenance)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl (2.0 micrograms/kg as premedication and 1.5 micrograms/kg during maintenance)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 50
Study: 8936893

Group type: EXPERIMENTAL
Intervention: Social support intervention for mothers of children with JRA over 15 months
Number of subjects: 0
Study: 8247819

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with an inspiratory pressure load equal to 30% of PImax
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham training with a light inspiratory pressure load
Number of subjects: 67
Study: 3546779

Group type: EXPERIMENTAL
Intervention: Oral diltiazem, 180 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral verapamil, 240 mg/day
Number of subjects: 32
Study: 29484548

Group type: EXPERIMENTAL
Intervention: Active periodontal therapy (subgingival debridement); systemic antibiotics prescribed if Aggregatibacter actinomycetemcomitans was detected (10 AgP, 8 ChP); flap surgery if required.
Number of subjects: 42
Study: 27788686

Group type: EXPERIMENTAL
Intervention: Exercise-assisted reduction to stop (EARS) smoking intervention
Number of subjects: 99
Study: 24787491

Group type: EXPERIMENTAL
Intervention: Automated Self-Administered 24-hour Recall (ASA24)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Interviewer-administered Automated Multiple-Pass Method (AMPM)
Number of subjects: 81
Study: 22394647

Group type: EXPERIMENTAL
Intervention: E-info geneca (pre-visit educational website)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 197
Study: 21095264

Group type: EXPERIMENTAL
Intervention: Intravenous epoetin α (up to 60,000 IU)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 18996930

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients supplementation
Number of subjects: 5828

Group type: EXPERIMENTAL
Intervention: Iron with folic acid supplementation
Number of subjects: 5828

Group type: COMPARATOR
Intervention: Folic acid supplementation
Number of subjects: 5828
Study: 15951327

Group type: EXPERIMENTAL
Intervention: i.v. tramadol 1.5 mg kg(‐1) and i.v. ketorolac 0.3 mg kg(‐1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 46
Study: 12460784

Group type: EXPERIMENTAL
Intervention: Ifosfamide 5 g/m(2) over 24 h (5 g/m(2)/1 day), every 3 weeks
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Ifosfamide 3 g/m(2) per day over 4 h on three consecutive days (3 g/m(2)/3 days), every 3 weeks
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Ifosfamide 5 g/m(2) over 24 h (5 g/m(2)/1 day), second-line treatment
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Ifosfamide 3 g/m(2) per day over 4 h on three consecutive days (3 g/m(2)/3 days), second-line treatment
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Ifosfamide 5 g/m(2) over 24 h (5 g/m(2)/1 day)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Ifosfamide 3 g/m(2) per day over 4 h on three consecutive days (3 g/m(2)/3 days)
Number of subjects: 182
Study: 10393490

Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic reviews and meta-analyses
Number of subjects: 0
Study: 7489439

Group type: EXPERIMENTAL
Intervention: Paracetamol plus ketorolac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no morphine)
Number of subjects: 0
Study: 1952133

Group type: EXPERIMENTAL
Intervention: Demand-dose PCEA (3 mL every 10 min without restriction)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI) (0.125% bupivacaine with fentanyl at 12 mL/h)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Demand-dose PCEA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 40
Study: 7030837

Group type: EXPERIMENTAL
Intervention: Prednisolone, 40 mg given orally on alternate days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29745688

Group type: EXPERIMENTAL
Intervention: Emotion regulation (measured by DERS)
Number of subjects: 290
Study: 29674314

Group type: EXPERIMENTAL
Intervention: mHealth app-based educational program (4-week access)
Number of subjects: 17
Study: 27390150

Group type: EXPERIMENTAL
Intervention: ABT-494 3 mg twice daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ABT-494 6 mg twice daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ABT-494 12 mg twice daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ABT-494 18 mg twice daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ABT-494 24 mg once daily
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 24861892

Group type: EXPERIMENTAL
Intervention: Post-T2DM diagnosis activity levels
Number of subjects: 2816

Group type: EXPERIMENTAL
Intervention: Adjusted post-T2DM diagnosis activity levels
Number of subjects: 2816
Study: 23095351

Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 233

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Acupuncture for severe IBS cases (Symptom Severity Score over 300)
Number of subjects: 233
Study: 20214462

Group type: EXPERIMENTAL
Intervention: Standard care plus Docobo HealthHUB monitors at home for 26 weeks followed by 26 weeks standard care (Tm Group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (Controls) for 52 weeks
Number of subjects: 40
Study: 17941871

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day plus hypolipaemic diet
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo plus hypolipaemic diet
Number of subjects: 204
Study: 15982813

Group type: EXPERIMENTAL
Intervention: Alfentanil (plasma concentration 70ng/ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Morphine high dose (plasma concentration 30ng/ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Morphine low dose (plasma concentration 15ng/ml)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Midazolam (active placebo, 20microg/kg for 10min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All drugs tested
Number of subjects: 16
Study: 12813380

Group type: EXPERIMENTAL
Intervention: Redon drains (RD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chest tubes (CT)
Number of subjects: 40
Study: 11263274

Group type: EXPERIMENTAL
Intervention: Xin Mai Tong Capsule
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between Xin Mai Tong group and Control group
Number of subjects: 40
Study: 8964881

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 24,25(OH)2 D3
Number of subjects: 15
Study: 1996531

Group type: EXPERIMENTAL
Intervention: PTFE grafts for initial femoropopliteal reconstruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autogenous saphenous vein for secondary repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: PTFE grafts for initial reconstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saphenous vein for initial reconstruction
Number of subjects: 0
Study: 6480127

Group type: EXPERIMENTAL
Intervention: Toluene at 100 ppm
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: MEK at 200 ppm
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Toluene (50 ppm) and MEK (100 ppm) in combination
Number of subjects: 144

Group type: COMPARATOR
Intervention: Ethanol at 0.08%
Number of subjects: 144
Study: 31783777

Group type: EXPERIMENTAL
Intervention: Brushing of the palate and immersion of the prosthesis in 0.15% triclosan solution
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Brushing of the palate and immersion of the prosthesis in lactose monohydrate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Brushing the palate with citric acid and immersing the prosthesis in lactose monohydrate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Brushing of the palate and immersion of the prosthesis in 0.25% sodium hypochlorite solution
Number of subjects: 100
Study: 29187474

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Minicholecystectomy (MC)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Inflammation of the gallbladder wall (IGW)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Correlation of IGW with plasma CRP levels
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Correlation of IGW with plasma GPX1 levels
Number of subjects: 114
Study: 27721534

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg once a day for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 24043482

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (n=31)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Medical Portland cement (n=29)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: White MTA (n=26)
Number of subjects: 86
Study: 22869566

Group type: EXPERIMENTAL
Intervention: 3 mg of liposomal amphotericin B/kg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg of liposomal amphotericin B/kg at time zero, followed by 5 mg/kg at 48 and 120 h
Number of subjects: 30
Study: 19713258

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Storz V‐Mac
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: McGrath
Number of subjects: 150
Study: 17208102

Group type: COMPARATOR
Intervention: Conventional pendulum appliances
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Palatal osseointegrated implants combined with pendulum springs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intergroup comparisons
Number of subjects: 30
Study: 15140263

Group type: EXPERIMENTAL
Intervention: PDM training approximately four weeks prior to the SPE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDM training approximately 12 weeks prior to the SPE
Number of subjects: 0

Group type: COMPARATOR
Intervention: No PDM training
Number of subjects: 0
Study: 10913921

Group type: EXPERIMENTAL
Intervention: Vertebral fracture group (31 women and 16 men)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-fracture group (22 women and 11 men)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both fracture and non-fracture groups
Number of subjects: 80
Study: 8757200

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1582124

Group type: EXPERIMENTAL
Intervention: Slow-releasing nicardipine (20 mg two times daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 2417476

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (Ch-XRT) - methotrexate, bleomycin, cisplatin with split-course irradiation (2,000 rad/10 preop., 4,000 rad/20 postop.)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard therapy (surgery and/or irradiation alone) - includes randomized control (RC) and concomitantly-treated (CC) patients
Number of subjects: 79
Study: 30756411

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 3 mL/kg 20% albumin over 30 minutes
Number of subjects: 30
Study: 29261824

Group type: EXPERIMENTAL
Intervention: Varenicline tartrate, 1 mg twice daily for 16 weeks
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Varenicline tartrate
Number of subjects: 131
Study: 26688003

Group type: EXPERIMENTAL
Intervention: Low-dose rituximab (two 375-mg/m2 infusions)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Full-dose rituximab (two 1000-mg infusions)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 22821022

Group type: EXPERIMENTAL
Intervention: Blended learning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture learning
Number of subjects: 0
Study: 19924007

Group type: EXPERIMENTAL
Intervention: Resistance plus whole-body vibration (SQTV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resistance training only (SQT)
Number of subjects: 30
Study: 18194413

Group type: EXPERIMENTAL
Intervention: Prophylactic Antithrombin Replacement in Kids with ALL treated with L‐Asparaginase (PARKAA) study
Number of subjects: 54

Group type: COMPARATOR
Intervention: Unselected childhood ALL survivors
Number of subjects: 54
Study: 15672001

Group type: EXPERIMENTAL
Intervention: Estradiol cypionate
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 12773303

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion for 60 min
Number of subjects: 8
Study: 10822909

Group type: EXPERIMENTAL
Intervention: CoQ10
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 8837409

Group type: EXPERIMENTAL
Intervention: Characters identified and tested verbally
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Characters identified and tested visually
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Imagined characters
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Seen characters
Number of subjects: 80
Study: 1614233

Group type: EXPERIMENTAL
Intervention: Clinical pharmacists' consultations
Number of subjects: 236
Study: 2860931

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buspirone 40 mg
Number of subjects: 24
Study: 30418593

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DHA-PQ)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Artemether-Lumefantrine (AL)
Number of subjects: 599
Study: 30122620

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.8 mg/kg with gemcitabine 1000 mg/m2
Number of subjects: 42
Study: 27605258

Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg once daily
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Ilaprazole 15 mg once daily
Number of subjects: 325

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 325
Study: 24562349

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) + tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: nevirapine (NVP) + tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 741
Study: 22009525

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (CIP IV) 300 mg b.i.d.
Number of subjects: 205

Group type: COMPARATOR
Intervention: Intravenous meropenem (MEM IV) 500 mg b.i.d.
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (CIP IV) 300 mg b.i.d. in upper gastrointestinal surgery patients.
Number of subjects: 205

Group type: COMPARATOR
Intervention: Intravenous meropenem (MEM IV) 500 mg b.i.d. in upper gastrointestinal surgery patients.
Number of subjects: 205
Study: 19936845

Group type: EXPERIMENTAL
Intervention: Price estimates provided by hospitals
Number of subjects: 353

Group type: COMPARATOR
Intervention: No response or incomplete information from hospitals
Number of subjects: 353
Study: 18611150

Group type: EXPERIMENTAL
Intervention: Bacopa monnieri extract 300 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 18578895

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Interpersonal Therapy (IPT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Pharmacotherapy (PHT)
Number of subjects: 130
Study: 15730064

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) alone or in combination with cognitive restructuring
Number of subjects: 69
Study: 11726307

Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl) containing chewing gum used up to 6 times daily for 10 min each occasion for 3 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-desensitising toothpaste
Number of subjects: 59
Study: 9234034

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate (MPH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Expectancy regarding medication
Number of subjects: 60
Study: 7685719

Group type: EXPERIMENTAL
Intervention: Local injection of hyperosmolar (50%) glucose solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Salpingostomy
Number of subjects: 40
Study: 3539128

Group type: EXPERIMENTAL
Intervention: Scopoderm TTS (SCOTTS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dimenhydrinate
Number of subjects: 20
Study: 11589870

Group type: EXPERIMENTAL
Intervention: Patients with large cup-to-disk ratios and both abnormal standard achromatic automated perimetry and short-wavelength automated perimetry (n = 22)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Patients with large cup-to-disk ratios and both normal standard achromatic automated perimetry and short-wavelength automated perimetry (n = 42)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Patients with large cup-to-disk ratios and abnormal short-wavelength automated perimetry only (n = 9)
Number of subjects: 76
Study: 30932134

Group type: EXPERIMENTAL
Intervention: 2RDA (2 times the recommended daily allowance of protein intake, 2g/kg/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: RDA (current recommended daily allowance of protein intake, 0.8g/kg/d)
Number of subjects: 26
Study: 29974946

Group type: EXPERIMENTAL
Intervention: Multidisciplinary patient care bundle intervention
Number of subjects: 0
Study: 26761382

Group type: EXPERIMENTAL
Intervention: HDTBR
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HDTBR (headache episodes)
Number of subjects: 12
Study: 24772415

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 65 mg kg(‐1) infusion in 250 mL 5% dextrose at 3.5 mL/min (Group M)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group received saline (Group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 65 mg kg(‐1) infusion (Group M)
Number of subjects: 40
Study: 23413492

Group type: EXPERIMENTAL
Intervention: HA gauze pad (ialuset gauze pad)
Number of subjects: 170

Group type: COMPARATOR
Intervention: HC dressing (DuoDERM E)
Number of subjects: 170
Study: 20036097

Group type: EXPERIMENTAL
Intervention: 30‐min in‐person pain education/communication intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 89
Study: 18608623

Group type: EXPERIMENTAL
Intervention: Family Weight School therapy program in group meetings
Number of subjects: 72

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 72
Study: 16003654

Group type: EXPERIMENTAL
Intervention: Standard protocol (STD)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Frequency reduction (FRD)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Weight reduction (WRD)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Repetition reduction (RRD)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control
Number of subjects: 58